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A B S T R A C T
Introduction: This review aims to evaluate the current evidence for the efﬁcacy of acupuncture in the
management of overactive bladder.
Methods: Fourteen databases will be searched from their inception, including PubMed, MEDLINE, AMED,
EMBASE, the Cochrane Library, six Korean Medical databases (Korean Studies Information Service
System, DBPIA, the Korean Institute of Science and Technology Information, the Research Information
Service System, KoreaMed, and the Korean National Assembly Library), the China National Knowledge
Infrastructure (CNKI), the Chongqing VIP Chinese Science and Technology Periodical (VIP), and Wanfang.
Only randomized clinical trials using acupuncture with or without electrical stimulation for overactive
bladder will be considered. The selection of the studies, data extraction, and assessment will be
performed independently by two researchers. The risk of bias will be assessed with the Cochrane risk of
bias.
Dissemination: The systematic review will be published in a peer-reviewed journal. The review will also
be disseminated electronically and in print. Updates of the review will be conducted to inform and guide
healthcare practice and policy.
Trial registration number: PROSPERO 2014:CRD42014010377.
ã 2016 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Overactive bladder (OAB) is a clinical diagnosis characterized by
the presence of bothersome urinary symptoms including urgency,
frequency, nocturia and urgency incontinence [1]. Most studies of
OAB, including studies from the International Continence Society
(ICS) [2] and the American Urological Association (AUA) guidelines
[1], exclude individuals with symptoms related to urinary tract
infections or other obvious pathology, such as neurological
conditions [3]. OAB is highly prevalent, estimates in a cross-
sectional population-representative survey have revealed that
10.9% and 14.6% of men and 22.5% and 33.7% of women in the UK
and Sweden, respectively, experience OAB [4]. Although OAB
symptoms with and without incontinence place a considerable* Corresponding author at: Clinical Research Division, Korea Institute of Oriental
Medicine, 461-24 Jeonmin-dong, Yuseong-gu, Daejeon 34054, Republic of Korea.
E-mail addresses: drmslee@gmail.com, mslee@kiom.re.kr (M.S. Lee).
http://dx.doi.org/10.1016/j.eujim.2016.08.161
1876-3820/ã 2016 The Author(s). Published by Elsevier GmbH. This is an open access burden on quality-of-life, quality-of-sleep, and mental health in
both men and women [5], medical options (both medication and
behavioral approaches) are only partially effective [6–8].
Acupuncture is deﬁned as a method of relieving symptoms or
curing illness by placing needles into the skin at particular points,
known as acupoints, on the body. Needles can be stimulated
electrically (electroacupuncture), and heat and moxibustion can be
applied through the needle [9].
A trial of 4 weekly acupuncture sessions showed the efﬁcacy of
treatment compared with sham acupuncture in 95 female subjects
with OAB [10]. Electroacupuncture at SP 6, referred to by urologists
as percutaneous posterior tibial nerve stimulation (PTNS), is
commonly examined for its effects on OAB [11].
A trial of electroacupuncture at SP6 has demonstrated the
efﬁcacy of this intervention compared with sham acupuncture in
220 subjects with OAB [12], Other studies suggest that acupunc-
ture compares favorably to tolterodine [13] and is a viable long
term therapy [14].article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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or hormonal effects [16] via peripheral and central mechanisms
[9,17]. Among the possible mechanisms, acupuncture and also
PTNS may act as methods of neuromodulation in controlling OAB,
as evidenced by purinergic signaling in the lower urinary tract
[18,19]. The mechanism of action of acupuncture induced the
stimulation of neuromodulation of the bladder is not precisely
understood. Mechanical stimulation seems to produce signaling
via the sensory ganglia and interneurons to the spinal cord which
modulates the activity of the motor neurons in the brain stem that
control autonomic function, including urogenital activity, such as
the detrusor and sphincter muscles. However, reliable evidence
has not been found.
Current pharmacotherapy for the OAB is only partially effective
with respect to efﬁcacy, tolerability, and long-term compliance [8].
Several studies support acupuncture [10,20] and PTNS [13,14,21–
23] as effective treatment options of OAB symptoms.
Several reviews of OAB or urinary incontinence have focused on
acupuncture [24] or included acupuncture as one of the treatment
modalities [25–27]. However, these reviews were either not
systematic, out dated or did not follow the formal recommenda-
tions of a systematic review [28]. Therefore, their conclusions are
unreliable. Hence, there is a great need for a systematic review of
acupuncture for OAB that presents current evidence in an unbiased
manner.
This review aims to systematically evaluate evidence pertaining
to the efﬁcacy of acupuncture for treating OAB from RCTs.
2. Methods
2.1. Study registration
The protocol of this systematic review has been registered on
PROSPERO 2014 (registration number: CRD42014010377).
2.2. Data sources
The following databases will be searched from their inception to
the current date: PubMed, MEDLINE, AMED, EMBASE, the Cochrane
Library, Korean Medical Databases (Korean Studies Information
Service System, DBPIA, the Korean Institute of Science and
Technology Information, the Research Information Service System,
KoreaMed, and the Korean National Assembly Library), the China
National Knowledge Infrastructure (CNKI), the Chongqing VIP
Chinese Science and Technology Periodical (VIP), and Wanfang.
Articles identiﬁed through reference lists of included studies and
relevant systematic reviews will be considered for inclusion based
on their title. Our search strategy will include the main keywords
‘acupuncture’ and ‘overactive bladder’ (Supplements 1). Study
selection will be documented and summarized in a Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) compliant ﬂow chart (http://www.prisma-statement.
org).
2.3. Eligibility criteria
2.3.1. Population
We will include populations with a diagnosis of OAB regardless
of age, gender, and race. Only studies in which there are an external
set of criteria will be used to screen participants for the condition
(e.g., criteria from the International Urogynecological Association
(IUGA)/ICS joint report on the terminology for female pelvic ﬂoor
dysfunction [2], AUA [1], and the ICS [29]).2.3.2. Interventions
Studies that evaluate any type of invasive acupuncture with or
without electrical stimulation will be included. The treatments
considered must involve needle insertion at acupuncture points,
pain points or trigger points and must be described as acupunc-
ture. Control interventions may include treatments such as general
conventional care (drugs, exercise, education, behavioral approach,
etc.), sham treatment (interventions mimicking ‘true’ acupunc-
ture/true treatment but deviating in at least one aspect considered
important by acupuncture theory, such as skin penetration or
correct point location), waiting list, or no-treatment. We will
exclude studies in which one form of acupuncture is compared
with a different form of acupuncture. Studies investigating other
methods of stimulating acupuncture points without needle
insertion (e.g., acupressure, pressed studs, and laser stimulation)
will be excluded.
2.3.3. Outcome measures
2.3.3.1. Primary outcomes.
- Total treatment efﬁcacy: the number of patients whose OAB
symptoms improve
- Quality of life: measured using a validated questionnaire, for
example, the International Consultation on Incontinence
Questionnaire (ICIQ) [30], Medical Outcomes Study Short-Form
20 [31], or the King's Health Questionnaire [32].
2.3.3.2. Secondary outcomes.
- Urinary function: change in urgency, frequency, nocturia and
urgency incontinence.
- Impact of symptoms: measured by validated questionnaires,
such as the Urinary incontinence questionnaire and urogenital
distress inventory [33] and the psychosocial adjustment to
illness scale [34].
- Change in symptoms: measured by a 100 mm Visual Analogue
Scale (VAS).
- Adverse events.
- Participant withdrawal.
2.3.4. Study design
Only RCTs will be included and must clearly report randomiza-
tion in their manuscript or title. Observational, cohort, case-
control, case series, qualitative studies, uncontrolled trials and
laboratory studies will be excluded.
2.4. Data extraction
All articles will be read by two independent reviewers who
extract data from the articles according to predeﬁned criteria. The
extracted data will include the ﬁrst author, year of publication,
country, sample size, age and gender of the participants,
acupuncture intervention, control intervention, main outcomes
and adverse effects. The extracted data will be tabulated
(Supplement 2) for future analysis. Details regarding the acupunc-
ture and control interventions will be extracted on the basis of the
revised Standards for Reporting Interventions in Clinical Trials of
Acupuncture (STRICTA) [35] (Supplement 3).
2.5. Risk of bias assessment
Quality assessment will be performed using the tool for ‘risk of
bias’ assessment from the Cochrane Handbook for Systematic
J.-I. Kim et al. / European Journal of Integrative Medicine 8 (2016) 875–878 877reviews of Interventions (Supplement 4) [36]. The following
characteristics will be assessed: (1) random sequence generation
(2) allocation concealment (3) blinding of participants and
personnel (4) blinding of outcome assessment (5) incomplete
outcome data (6) selective outcome reporting and (7) other
sources of bias (we will evaluate baseline imbalance). This review
will use ‘L, U and H’ as a key for these judgments, where ‘Low’ (L)
indicates a low risk of bias, ‘Unclear’ (U) indicates that the risk of
bias is uncertain, and ‘High’ (H) indicates a high risk of bias.
Disagreements will be resolved by discussion among all authors.
The risk of bias assessment for included studies will be
summarized in a table, and the results and implications will be
critically discussed.
2.6. Data synthesis
All statistical analyses will be conducted using the Cochrane
Collaboration’s software program, Review Manager (RevMan),
V.5.3 for Windows (Copenhagen, The Nordic Cochrane Center).
Differences between the intervention and control groups will be
assessed. In the analysis of clinical efﬁcacy, categorical data will be
assessed in terms of risk ratio (RR), and continuous data will be
assessed in terms of standardized mean difference (SMD) for
considering the consistency. Categorical and continuous variables
will be expressed as efﬁcacy values with 95% conﬁdence intervals
(CIs). If the meta-analyses exhibit heterogeneity (deﬁned as results
of tests of heterogeneity that indicate a value of p < 0.1 by chi
square test and Higgins I2 50%), subgroup analyses will be
explored to determine the cause of clinical heterogeneity. A
random effects model will be used to assess combined effect size
from efﬁcacy variables because clinical heterogeneity is highly
expected across the included studies from the diversity of
interventions, study design, and other conditions. Publication bias
will be assed using funnel plots and Egger’s regression method
[37]. If missing data are detected, we will request any missing or
incomplete information from the original study investigators.
Subgroup analyses will be conducted according to different control
interventions (sham acupuncture vs conventional medication), the
type of acupuncture (Asian vs Western or PTNS), type of
stimulation (manual vs electric), acupuncture points (one or two
points vs multiple points), the design of the trial (acupuncture vs
sham acupuncture; acupuncture vs conventional medication; and
acupuncture combined with conventional medication vs conven-
tional medication) and country where the study conducted (Asian
vs Western). Where appropriate, a sensitivity analysis will be
performed to evaluate the robustness of the meta-analysis results.
To determine consistency with other meta-analyses and meta-
regressions, the primary quality measure will be a binary measure
of allocation concealment [38].
3. Dissemination
To date, one systematic review of urinary incontinence has been
published [24]. The authors concluded that results supporting
acupuncture as an effective treatment for urinary incontinence in
the 4 databases searched were limited. Our systematic review will
update and provide a detailed summary of the current evidence
related to the efﬁcacy of acupuncture in treating the symptoms of
patients with OAB. This evidence will be useful to practitioners,
patients and health policy-makers regarding the use of acupunc-
ture in OAB treatment.
Conﬂict of interest statement
The authors declare that they have no potential conﬂict of
interest.Acknowledgments
JAL, TYC, JHJ, JC and MSL were supported by Korea Institute of
Oriental Medicine (K162921 and K16111).
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.eujim.2016.
08.161.
References
[1] E.A. Gormley, D.J. Lightner, K.L. Burgio, T.C. Chai, J.Q. Clemens, D.J. Culkin, A.K.
Das, H.E. Foster Jr., H.M. Scarpero, C.D. Tessier, S.P. Vasavada, Diagnosis and
treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU
guideline, J. Urol. 188 (6 Suppl) (2012) 2455–2463.
[2] B.T. Haylen, D. de Ridder, R.M. Freeman, S.E. Swift, B. Berghmans, J. Lee, A.
Monga, E. Petri, D.E. Rizk, P.K. Sand, G.N. Schaer, An International
Urogynecological Association (IUGA)/International Continence Society (ICS)
joint report on the terminology for female pelvic ﬂoor dysfunction, Neurourol.
Urodyn. 29 (1) (2010) 4–20.
[3] P. Abrams, L. Cardozo, M. Fall, D. Grifﬁths, P. Rosier, U. Ulmsten, P. Van
Kerrebroeck, A. Victor, A. Wein, The standardisation of terminology in lower
urinary tract function: report from the standardisation sub-committee of the
International Continence Society, Urology 61 (1) (2003) 37–49.
[4] K.S. Coyne, C.C. Sexton, Z.S. Kopp, C. Ebel-Bitoun, I. Milsom, C. Chapple, The
impact of overactive bladder on mental health, work productivity and health-
related quality of life in the UK and Sweden: results from EpiLUTS, BJU Int. 108
(9) (2011) 1459–1471.
[5] W.F. Stewart, J.B. Van Rooyen, G.W. Cundiff, P. Abrams, A.R. Herzog, R. Corey, T.
L. Hunt, A.J. Wein, Prevalence and burden of overactive bladder in the United
States, World J. Urol. 20 (6) (2003) 327–336.
[6] American urogynecological society’s guidelines development committee,
diagnosis and treatment of overactive bladder, Female Pelvic Med.
Reconstruct. Surg. 19 (6) (2013) 316.
[7] J.M. Bartley, E.S. Blum, L.T. Sirls, K.M. Peters, Understanding clinic options for
overactive bladder, Curr. Urol. Rep. 14 (6) (2013) 541–548.
[8] J. Jayarajan, S.B. Radomski, Pharmacotherapy of overactive bladder in adults: a
review of efﬁcacy, tolerability, and quality of life, Res. Rep. Urol. 6 (2013) 1–16.
[9] Z.Q. Zhao, Neural mechanism underlying acupuncture analgesia, Prog.
Neurobiol. 85 (4) (2008) 355–375.
[10] S.L. Emmons, L. Otto, Acupuncture for overactive bladder: a randomized
controlled trial, Obstet. Gynecol. 106 (1) (2005) 138–143.
[11] M. Cummings, The latest evidence for acupuncture – updated Nov 2013,
Accessed at http://www.medical-acupuncture.co.uk/LinkClick.aspx?
ﬁleticket=I4kGU27HT_g%3D&tabid=130. 2014 (5th, August) (2013).
[12] K.M. Peters, D.J. Carrico, R.A. Perez-Marrero, A.U. Khan, L.S. Wooldridge, G.L.
Davis, S.A. Macdiarmid, Randomized trial of percutaneous tibial nerve
stimulation versus Sham efﬁcacy in the treatment of overactive bladder
syndrome: results from the SUmiT trial, J. Urol. 183 (4) (2010) 1438–1443.
[13] K.M. Peters, S.A. Macdiarmid, L.S. Wooldridge, F.C. Leong, S.A. Shobeiri, E.S.
Rovner, S.W. Siegel, S.B. Tate, B.K. Jarnagin, P.L. Rosenblatt, B.A. Feagins,
Randomized trial of percutaneous tibial nerve stimulation versus extended-
release tolterodine: results from the overactive bladder innovative therapy
trial, J. Urol. 182 (3) (2009) 1055–1061.
[14] S.A. MacDiarmid, K.M. Peters, S.A. Shobeiri, L.S. Wooldridge, E.S. Rovner, F.C.
Leong, S.W. Siegel, S.B. Tate, B.A. Feagins, Long-term durability of percutaneous
tibial nerve stimulation for the treatment of overactive bladder, J. Urol. 183 (1)
(2010) 234–240.
[15] J.S. Han, Acupuncture analgesia: areas of consensus and controversy, Pain 152
(3 Suppl) (2011) S41–S48.
[16] J.S. Yu, B.Y. Zeng, C.L. Hsieh, Acupuncture stimulation and neuroendocrine
regulation, Int. Rev. Neurobiol. 111 (2013) 125–140.
[17] H. Jiang, P.J. Wang, H.W. Zeng, X.H. Zhao, Central mechanism of electric-
acupuncture at Zusanli (ST36) for gastric mucous membrane protection with
FMRI, Zhonghua Yi Xue Za Zhi 90 (21) (2010) 1458–1462.
[18] G. Burnstock, Acupuncture: a novel hypothesis for the involvement of
purinergic signalling, Med. Hypotheses 73 (4) (2009) 470–472.
[19] G. Burnstock, Purinergic signalling in the lower urinary tract, Acta Physiol.
(Oxf.) 207 (1) (2013) 40–52.
[20] Y. Aydogmus, M. Sunay, H. Arslan, A. Aydin, A.K. Adiloglu, H. Sahin,
Acupuncture versus solifenacin for treatment of overactive bladder and its
correlation with urine nerve growth factor levels: a randomized, placebo-
controlled clinical trial, Urol. Int. 93 (4) (2014) 437–443.
[21] M. Sancaktar, S.T. Ceyhan, I. Akyol, M. Muhcu, I. Alanbay, C. Mutlu Ercan, V.
Atay, The outcome of adding peripheral neuromodulation (Stoller afferent
neuro-stimulation) to anti-muscarinic therapy in women with severe
overactive bladder, Gynecol. Endocrinol. 26 (10) (2010) 729–732.
[22] H.C. Klingler, A. Pycha, J. Schmidbauer, M. Marberger, Use of peripheral
neuromodulation of the S3 region for treatment of detrusor overactivity: a
urodynamic-based study, Urology 56 (5) (2000) 766–771.
878 J.-I. Kim et al. / European Journal of Integrative Medicine 8 (2016) 875–878[23] M.R. van Balken, V. Vandoninck, K.W. Gisolf, H. Vergunst, L.A. Kiemeney, F.M.
Debruyne, B.L. Bemelmans, Posterior tibial nerve stimulation as
neuromodulative treatment of lower urinary tract dysfunction, J. Urol. 166 (3)
(2001) 914–918.
[24] S.H. Paik, S.R. Han, O.J. Kwon, Y.M. Ahn, B.C. Lee, S.Y. Ahn, Acupuncture for the
treatment of urinary incontinence: a review of randomized controlled trials,
Exp. Ther. Med. 6 (3) (2013) 773–780.
[25] K.E. Hartmann, M.L. McPheeters, D.H. Biller, R.M. Ward, J.N. McKoy, R.N.
Jerome, S.R. Micucci, L. Meints, J.A. Fisher, T.A. Scott, J.C. Slaughter, J.D. Blume,
Treatment of overactive bladder in women, Evid. Rep. Technol. Assess. (187)
(2009) 1–120.
[26] N. Christoﬁ, A. Hextall, An evidence-based approach to lifestyle interventions
in urogynaecology, Menopause Int. 13 (4) (2007) 154–158.
[27] C. Persson de Geeter, Overactive bladder syndrome in children, Urologe A 43
(7) (2004) 807–812.
[28] N. Panic, E. Leoncini, G. de Belvis, W. Ricciardi, S. Boccia, Evaluation of the
endorsement of the preferred reporting items for systematic reviews and
meta-analysis (PRISMA) statement on the quality of published systematic
review and meta-analyses, PLoS One 8 (12) (2013) e83138.
[29] M.J. Drake, Do we need a new deﬁnition of the overactive bladder syndrome?
ICI-RS 2013, Neurourol. Urodyn. 33 (5) (2014) 622–624.
[30] K. Coyne, C. Kelleher, Patient reported outcomes: the ICIQ and the state of the
art, Neurourol. Urodyn. 29 (4) (2010) 645–651.
[31] J.N. Liberman, T.L. Hunt, W.F. Stewart, A. Wein, Z. Zhou, A.R. Herzog, R.B. Lipton,
A.C. Diokno, Health-related quality of life among adults with symptoms of
overactive bladder: results from a U.S. community-based survey, Urology 57
(6) (2001) 1044–1050.[32] M. Vij, S. Srikrishna, D. Robinson, L. Cardozo, Quality assurance in quality of life
assessment-measuring the validity of the King's Health Questionnaire, Int.
Urogynecol. J. 25 (8) (2014) 1133–1135.
[33] J.S. Uebersax, J.F. Wyman, S.A. Shumaker, D.K. McClish, J.A. Fantl, Short forms to
assess life quality and symptom distress for urinary incontinence in women:
the Incontinence Impact Questionnaire and the Urogenital Distress Inventory.
Continence Program for Women Research Group, Neurourol. Urodyn. 14 (2)
(1995) 131–139.
[34] K.L. Hullﬁsh, D.E. Fenner, S.A. Sorser, J. Visger, A. Clayton, W.D. Steers,
Postpartum depression, urge urinary incontinence, and overactive bladder
syndrome: is there an association? Int. Urogynecol. J. Pelvic Floor Dysfunct. 18
(10) (2007) 1121–1126.
[35] H. MacPherson, D.G. Altman, R. Hammerschlag, L. Youping, W. Taixiang, A.
White, D. Moher, Revised STandards for Reporting Interventions in Clinical
Trials of Acupuncture (STRICTA): extending the CONSORT statement, PLoS
Med. 7 (6) (2010) e1000261.
[36] J. Higgins, D. Altman, J. Sterne, Chapter 8: assessing risk of bias in included
studies. In: J.P.T. Higgins, S. Green (Eds.), Cochrane handbook for systematic
reviews of interventions version, The Cochrane collaboration (updated March
2011).
[37] M. Egger, G. Davey Smith, M. Schneider, C. Minder, Bias in meta-analysis
detected by a simple, graphical test, BMJ 315 (7109) (1997) 629–634.
[38] C. Hewitt, S. Hahn, D.J. Torgerson, J. Watson, J.M. Bland, Adequacy and
reporting of allocation concealment: review of recent trials published in four
general medical journals, BMJ 330 (7499) (2005) 1057–1058.
